Cefotiam therapy of lower respiratory tract infections | Zendy

Michael A. Polis | Zendy; Carmelita U. Tuazon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cefotiam therapy of lower respiratory tract infections

Author(s) -

Michael A. Polis,

Carmelita U. Tuazon

Publication year - 1985

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.28.4.576

Subject(s) - cefotiam , streptococcus pneumoniae , respiratory tract infections , sputum , haemophilus influenzae , klebsiella pneumoniae , antibiotics , respiratory tract , microbiology and biotechnology , medicine , lower respiratory tract infection , respiratory system , cephalosporin , biology , pathology , tuberculosis , escherichia coli , biochemistry , gene

Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research